SCIENTIFIC ADVISORS

David S. Ettinger, M.D. is the SAB Member for Study 103.

Dr. Ettinger is a Professor of Oncology at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He is also a professor of medicine, otolaryngology, head and neck surgery, gynecology and obstetrics, and radiation oncology and molecular radiation sciences. He is the Chairman of NCCN guideline for NSCLC and Board of Directors of NCCN guideline.

Yuankai Shi, M.D. is the Principal Investigator for Study 105 and Study 106 in China.

Dr. Shi is the Associate Dean and Director of Oncology at Cancer Hospital of Chinese Academy of Medical Sciences and Associate Director of the Chinese Medical Association Hematology Branch. He is the Chairman of the NCCN guidelines for neutropenia management in China.

Jeffrey Crawford, M.D. is the DSMB Chairman for Study 105 and Study 106.

Dr. Crawford is a Professor of Medicine at Duke University. He is the Chairman of NCCN guidelines for neutropenia management in the U.S. and was the lead investigator of the U.S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen), which received approval from Food and Drug Administration in 1991.

Douglas W. Blayney, M.D. is the Principal Investigator for Study 105 and Study 106.

Dr. Blayney is a Professor of Medicine (Oncology) at Stanford University and former Medical Director of Stanford Cancer Center. He is a founding member and former board member of the NCCN Guidelines for neutropenia management in US, former president of the American Society of Clinical Oncology (ASCO) and has served on the Food and Drug Administration’s Oncologic Drugs Advisory Committee.

Peony Yu, M.D. is our SAB member.

Dr. Yu is Chief Medical Officer of FibroGen. She has more than 25 years of pharmaceutical leadership, patient care, and drug development experience with deep expertise in all aspects of clinical and regulatory process, and with multiple prior successful NDA/MAAs for novel drugs and drug/device combos. Prior to joining FibroGen, Dr. Yu served as Vice President of Clinical Research at Anesiva Inc. Previously, Dr. Yu was Director of Clinical Development at ALZA Corporation (now Johnson & Johnson); Director of Clinical Development at Pain Therapeutics Inc.; and Assistant Director, Clinical Development, at Elan Corporation plc (now Perrigo Company plc). Earlier in her career, Dr. Yu was Head of the Department of Physical Medicine & Rehabilitation at the Palo Alto Medical Foundation. Dr. Yu received a B.S. in Chemical Engineering from University of California, Davis, and an M.D. from the UC Davis School of Medicine. She completed her residency training at Stanford University School of Medicine. Dr. Yu is a native of China.

Avram Hershko, M.D. is SAB member for the ubiquitination platform.

Dr. Hershko has nearly 50 years of research leadership in ubiquitination pathway. He is laureate of the 2004 Nobel Prize in Chemistry for the discovery of the ubiquitin-mediated protein degradation. He is Distinguished Professor at Rappaport Faculty of Medicine at Technion in Haifa.

Yan Sun, M.D. is the Principal Investigator for Study 103 in China.

Dr. Sun is the Director of GCP Center at Cancer Hospital of Chinese Academy of Medical Sciences. He is the co-founder of the Steering Committee of the Chinese Society of Clinical Oncology (CSCO). He is also the Chairman of the NCCN guidelines for NSCLC in China.

Douglas W. Blayney, M.D. is the Principal Investigator for Study 105 and Study 106.

Dr. Blayney is a Professor of Medicine (Oncology) at Stanford University and former Medical Director of Stanford Cancer Center. He is a founding member and former board member of the NCCN Guidelines for neutropenia management in US, former president of the American Society of Clinical Oncology (ASCO) and has served on the Food and Drug Administration’s Oncologic Drugs Advisory Committee.

Jeffrey Crawford, M.D. is the DSMB Chairman for Study 105 and Study 106.

Dr. Crawford is a Professor of Medicine at Duke University. He is the Chairman of NCCN guidelines for neutropenia management in the U.S. and was the lead investigator of the U.S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen), which received approval from Food and Drug Administration in 1991.

Yuankai Shi, M.D. is the Principal Investigator for Study 105 and Study 106 in China.

Dr. Shi is the Associate Dean and Director of Oncology at Cancer Hospital of Chinese Academy of Medical Sciences and Associate Director of the Chinese Medical Association Hematology Branch. He is the Chairman of the NCCN guidelines for neutropenia management in China.

David S. Ettinger, M.D. is the SAB Member for Study 103.

Dr. Ettinger is a Professor of Oncology at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He is also a professor of medicine, otolaryngology, head and neck surgery, gynecology and obstetrics, and radiation oncology and molecular radiation sciences. He is the Chairman of NCCN guideline for NSCLC and Board of Directors of NCCN guideline.

Yan Sun, M.D. is the Principal Investigator for Study 103 in China.

Dr. Sun is the Director of GCP Center at Cancer Hospital of Chinese Academy of Medical Sciences. He is the co-founder of the Steering Committee of the Chinese Society of Clinical Oncology (CSCO). He is also the Chairman of the NCCN guidelines for NSCLC in China.

Avram Hershko, M.D. is SAB member for the ubiquitination platform.

Dr. Hershko has nearly 50 years of research leadership in ubiquitination pathway. He is laureate of the 2004 Nobel Prize in Chemistry for the discovery of the ubiquitin-mediated protein degradation. He is Distinguished Professor at Rappaport Faculty of Medicine at Technion in Haifa.